# Inventiva S.A. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Inventiva S.A.). ## Overview Inventiva S.A. is a France-based biopharmaceutical company focused on the discovery and clinical development of oral small-molecule therapies. Its principal development program is lanifibranor, a drug candidate being advanced for metabolic and fibrotic diseases, especially MASH. The company is publicly listed in France and the United States. ## Products & services • Lanifibranor clinical development program • Oral small-molecule drug discovery • Metabolic and fibrotic disease therapies • Preclinical and clinical research programs • Regulatory and development collaboration partnerships - **Lanifibranor** (90%) — The company's lead clinical candidate for metabolic and fibrotic diseases, including MASH. - **Pipeline R&D** (5%) — Early-stage discovery, preclinical work, and additional research programs around new therapeutics. - **Collaborations and partnerships** (5%) — Research, development, and commercialization partnerships supporting program advancement. - Lanifibranor clinical development program - Oral small-molecule drug discovery - Metabolic and fibrotic disease therapies - Preclinical and clinical research programs - Regulatory and development collaboration partnerships ## Customers Inventiva does not sell a broad commercial product portfolio; its immediate counterparties are clinical investigators, research partners, regulators, and capital providers that support development of its drug candidates. If lanifibranor is successfully approved and commercialized, customers would expand to physicians, hospitals, and patients in the relevant therapeutic areas. - **Clinical research partners** (primary) — Trial sites, investigators, and CRO-style collaborators that execute studies and generate development data. - **Regulatory authorities** (primary) — Health agencies that review clinical results and determine whether product candidates can advance to approval. - **Future prescribers** (secondary) — Specialists and physicians who would prescribe lanifibranor if approved for metabolic liver disease. - **Future patients** (secondary) — Patients with MASH or related fibrotic/metabolic conditions who would be treated with the approved therapy. - **Development partners** (primary) — Companies or institutions that co-develop, finance, or support the pipeline through partnerships. - Clinical investigators and trial sites running studies - Research partners supporting preclinical and clinical programs - Regulators reviewing development and approval dossiers - Future prescribers in metabolic liver disease and fibrosis - Future patients needing oral therapies for MASH or related diseases ## Geography Inventiva is headquartered in France and is listed on Euronext Paris and Nasdaq in the United States. Its operations are centered on European and U.S. drug development activities, with clinical and regulatory work tied to global trial sites and potential commercialization markets. - Headquartered in France - Listed on Euronext Paris and Nasdaq Global Market - Clinical development spans Europe and the United States - Future commercialization would depend on major pharmaceutical markets - Trial execution and regulatory review are multinational ## Strategy Inventiva’s strategy is centered on advancing lanifibranor through pivotal clinical development, seeking regulatory approval, and preparing for possible commercialization. It also depends on partnerships and financing to support long development timelines typical of biotechnology programs. - **Complete pivotal lanifibranor development** (short-term) — Late-stage clinical data is the key gate to regulatory review and eventual commercialization. - **Pursue regulatory submission** (medium-term) — Approval is required to convert the pipeline into a commercial product business. - **Strengthen financing and partnerships** (short-term) — Clinical development is capital intensive and partnerships can extend runway and de-risk commercialization. - Advance lanifibranor through Phase 3 development - Prepare regulatory submission package for MASH - Build commercial, manufacturing, and launch capabilities - Use partnerships to share development and commercialization burden - Secure funding to support long-duration clinical programs ## Risks Inventiva is exposed to clinical trial failure, regulatory setbacks, and the need to continuously fund a long and capital-intensive development path. Because lanifibranor is the core value driver, any negative data, delays, or financing shortfalls could materially impair the company’s ability to continue development or commercialize its pipeline. - **Lanifibranor clinical failure** [critical] — The company's valuation and future commercialization depend heavily on one lead candidate. - **Regulatory delay or non-approval** [high] — Even positive data may not be sufficient for an approval filing or label expansion. - **Financing and going-concern pressure** [critical] — The business requires external capital before product sales can fund operations. - **Partnering and execution risk** [medium] — Delays or disagreements with collaborators can slow clinical and commercial plans. - **Patent and collateral encumbrance** [high] — Debt financing has granted lenders security interests over key assets, including patents. - Clinical trial failure could eliminate the lead asset's value - Regulatory authorities may request more data or trial changes - Financing risk is high because the company has no product revenue - Partnering risk affects development speed and commercial access - Security interests over key patents increase lender dependence ## Accounting As a development-stage biotechnology company, Inventiva's reported results are shaped by research and development expense, capitalized financing structures, and judgments around going-concern assessment. The company's filings also highlight debt financing, security interests, and potential warrant issuance, which can create complex accounting for financing instruments, dilution, and contingent outcomes. - **Research and development expense** — Affects operating results and comparability across periods - **Going-concern evaluation** — Can materially affect disclosures and investor perception - **Debt financing instruments** — Can affect liabilities, equity, and finance costs - **Impairment of intangible assets** — Could trigger large non-cash charges if value declines - R&D expense recognition dominates reported operating costs - Going-concern assessment depends on cash runway and financing access - Debt financing and warrants may require complex instrument accounting - Share-based and dilutive instruments affect per-share analysis - Asset impairment risk is tied to clinical and patent outcomes --- *Last updated: 2026-09-28T12:04:07.796464+00:00*